Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study-Reference-Cited by-同舟云学术

Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study

Published:2017-05-22 Issue:6 Volume:108 Page:1231-1239
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Oya Mototsugu¹^ORCID,Tomita Yoshihiko²,Fukasawa Satoshi³,Shinohara Nobuo⁴,Habuchi Tomonori⁵,Rini Brian I.⁶,Fujii Yosuke⁷,Kamei Yoichi⁷,Umeyama Yoshiko⁷,Bair Angel H.⁸,Uemura Hirotsugu⁹

Affiliation:

1. Department of Urology; Keio University School of Medicine; Tokyo Japan

2. Department of Urology; Yamagata University Faculty of Medicine; Yamagata Japan

3. Prostate Center and Division of Urology; Chiba Cancer Center; Chiba Japan

4. Department of Urology; Hokkaido University Graduate School of Medicine; Hokkaido Japan

5. Department of Urology; Akita University School of Medicine; Akita Japan

6. Department of Solid Tumor Oncology; Cleveland Clinic; Taussig Cancer Institute; Cleveland Ohio USA

7. Pfizer Japan; Tokyo Japan

8. Pfizer Oncology; San Diego California USA

9. Department of Urology; Kindai University Faculty of Medicine; Osaka Japan

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13232/fullpdf

Reference17 articles.

1. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial;Rini;Lancet,2011

2. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial;Motzer;Lancet Oncol,2013

3. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial;Hutson;Lancet Oncol,2013

4. Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial;Hutson;Clin Genitourin Cancer,2017

5. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Kidney Cancer version 3.2016 2016 https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor‐targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer;International Journal of Urology;2024-02-06

2. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101;ESMO Open;2023-12

3. Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information;Journal of Clinical Epidemiology;2022-10

4. Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101;ESMO Open;2022-10

5. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101;ESMO Open;2022-04